Antiplatelet therapy - choose aspirin!
Aspirin is the most widely studied antiplatelet drug. On the basis of >100 randomized trials in high-risk patients, aspirin is shown to reduce vascular death by ~15% and non-fatal vascular events by ~30%(1)
Ideal dosage - choose 100mg!
The indirect comparisons reported in the overview of Antithrombotic Trialists Collaboration summarised 12 trials with a total of 6,776 high risk patients, confirmed that doses between 75-150 mg daily reduced vascular events by 26-38%. Doses over 160 mg reduced these odds by up to 22% according to another 53 trials (48,964 patients) while doses less than 75 mg dropped to as low as 5% evidenced by 3 trials and 3,655 patients (1)
Administration - choose "regular" Aspirin!
The oral bioavailability of regular aspirin tablets is ~40% to ~50% over a wide range of doses. A considerably lower bioavailability has been reported for enteric-coated tablets and for sustained-release, microencapsulated preparations.(3) Enteric-coated formulations do not modify the risk of upper gastrointestinal complications in the general population of low-dose aspirin.(4)
Affordability - choose MYOPRIN!
Myoprin 100 mg Tablets are the most affordable low dose aspirin available and are supplied in a convenient quality monthly pack with with easy-to-tear foil packaging(5)
124 Elevation Avenue, Randjesfontein, Midrand, 1683, South Africa
Postnet Suite 319, Private Bag X1007, Lyttelton, 0140, South Africa
Ph +27 (0)11 314 2366 | Fax +27 (0)86 600 6315 | info@ipharma.co.za
For all business related queries email: natalie@ipharma.co.za
www.ipharma.co.za
For all product Adverse Drug Reactions (ADRs) and/or Adverse Drug Events (ADEs) or complaints kindly contact the PV Officer, Natalie Hime using natalie@ipharma.co.za
Pharmacovigilance contact number 083 258 6226 (Patients/reporters can use during or after-hours).